Join Dr. Christy Russell (VP, US Medical Affairs at Exact Sciences) as she reviews new data presented at SABCS 2021 and their implications for clinical management of breast cancer patients. Included will be an in-depth discussion of the latest data from the landmark RxPONDER trial. Dr. Russell will be available for a live Q&A following the presentation
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
CTO, US Medical Affairs
Precision Oncology
Vice President, US Medical Affairs, Precision Oncology
At SABCS 2020, Kevin Kalinsky, MD presented early RxPONDER data.
RxPONDER study results are expected to be practice-changing for N1 HR+, HER2-, early breast cancer patients
References
